Stephanou is an accomplished leader in the pharmaceutical industry with over thirty years of experience in manufacturing operations and engineering
IPS, a provider of architecture, engineering, procurement, construction management, and validation services for the life sciences sector, has announced the appointment of Jim Stephanou as its new Chief Executive Officer (CEO) to lead the company into its next phase of growth.
Stephanou is a well-recognised and accomplished leader in the pharmaceutical industry with over thirty years of experience in manufacturing operations and engineering. His most recent role was VP of Global Engineering Solutions at Merck & Co, a position he held for eight years.
During that time, he was responsible for managing and overseeing one of the largest capital investment cycles of any pharmaceutical operating company.
Before joining Merck, Stephanou held several leadership positions at Bayer Corporation and Lyondell Basell Industries for over two decades. He holds a mechanical engineering degree from Drexel University.
It is truly an exciting time to join the company. IPS has a strong foundation and a talented team
- Jim Stephanou, CEO of IPS
Stephanou will report to Dave Goswami, the Global CEO of IPS Enterprise.
When discussing the new CEO appointment for IPS Life Science, Goswami said: “We are excited to have someone of Jim’s calibre to take on the CEO role. Jim is just the right person to lead IPS Life Science as we continue our unwavering commitment to providing EPCMV services to the life sciences industry."
Goswami added: "I’ve had the pleasure of working with and getting to know Jim through the many years supporting Merck as one of our largest clients. He has demonstrated remarkable leadership capabilities and possesses the skills necessary to lead IPS into the future. I have full faith in his ability to build upon our past accomplishments and drive the company to even greater heights."
Jim Stephanou shared his excitement about joining IPS: “I am thrilled and honoured to have the opportunity to lead such a respected and successful organisation. IPS has been in the midst of phenomenal growth that has led to becoming a part of Berkshire Hathaway’s group of companies. It is truly an exciting time to join the company."
The new CEO added: "IPS has a strong foundation, a talented team, and a reputation for excellence in the life sciences industry. I look forward to working closely with the team to further enhance our global brand and market presence and deliver innovative solutions to meet our client’s needs.”